NCT04465357View on ClinicalTrials.gov

Efficacy of Erenumab on Functional Impact of Migraine

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

June 3, 2022

Study Completion Date

June 3, 2022

Conditions
Migraine
Interventions
DRUG

Erenumab-Aooe 140 MG/ML [Aimovig]

140 mg/mL administered subcutaneously

Trial Locations (3)

60642

Diamond Headache Clinic, Chicago

63303

StudyMetrix, City of Saint Peters

65810

Clinvest Research, Springfield

Sponsors

Collaborators (1)

Clinvest Research, LLC
All Listed Sponsors
collaborator

Clinvest Research, LLC

INDUSTRY

collaborator

Smith, Timothy R., M.D.

INDIV

lead

Merle Diamond

OTHER

NCT04465357 - Efficacy of Erenumab on Functional Impact of Migraine | Biotech Hunter | Biotech Hunter